Member
|
|
Join Date: Mar 2013
Location: New Jersey
Posts: 832
|
|
Member
Join Date: Mar 2013
Location: New Jersey
Posts: 832
|
NeuroDerm will release top-line results from phase II trial
NeuroDerm will release top-line results for ND0612L from a phase II study in patients with moderate Parkinson's patients, and preliminary interim results from a phase IIA study of ND0612H and ND0612L in advanced Parkinson's patients, at The Michael J. Fox Foundation's 2014 Parkinson's Disease Therapeutics Conference, on October 29th in New York, NY.
As Duodopa still has not yet received US FDA approval, NeuroDerm's ND0612L may make it obsolete before it ever hits the market.
|